ECOVERY FROM high-dose chemotherapy has been enhanced by the use of autologous bone marrow (BM) transplantation. Recently, there has been increased use of mobilized peripheral blood (PB) hematopoietic progenitors in place of BM because of reduced engraftment times.'.' Progenitors in the PB are rare, but their numbers can be increased with chemotherapeutic agents such as cyclophosphamide.3 Growth factors that have been shown to induce mobilization include granulocyte-macrophage colony-stimuIating factor (GM-csF),~.~ granulocyte colony-stimulating factor (G-CSF).7.8 c-kit ligand (KL; also known as mast cell growth factor, Steel factor, and stem cell factor)," interleukin-l2 (IL-12),Io IL-7," and IL-Wmacrophage inflammatory protein-la (MIP-la) family members.12.13
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We have investigated the effects of in vivo treatment with flt3 ligand (FL) on murine hematopoiesis, including mobilization of progenitors into the peripheral blood (PB). Mice were injected once daily with 10 p g recombinant human FL for 15 days. On days 3,5,8,10,15, and 22, mice were killed and analyzed for the number of leukocytes and colony-forming units (CFU) in bone marrow (BM), spleen, and PB. Splenic and PB cellularity increased with time in FL-treated mice. In the spleen, there was an increase in B cells, myeloid cells, and nucleated erythroid cells; in the PB, there was an increase in lymphocytes, granulocytes, and monocytic cells. The maximal number of CFU in the BM was observed after 3 days of FL treatment, giving 3.7-and 7.3-fold increases in CFU-granulocyte-macrophage (CFU-GM) and CFU-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM), respectively, compared with mouse serum albumin (MSAI-ECOVERY FROM high-dose chemotherapy has been enhanced by the use of autologous bone marrow (BM) transplantation. Recently, there has been increased use of mobilized peripheral blood (PB) hematopoietic progenitors in place of BM because of reduced engraftment times.'.' Progenitors in the PB are rare, but their numbers can be increased with chemotherapeutic agents such as cyclophosphamide.3 Growth factors that have been shown to induce mobilization include granulocyte-macrophage colony-stimuIating factor (GM-csF),~.~ granulocyte colony-stimulating factor (G-CSF).7.8 c-kit ligand (KL; also known as mast cell growth factor, Steel factor, and stem cell factor)," interleukin-l2 (IL-12),Io IL-7," and IL-Wmacrophage inflammatory protein-la (MIP-la) family members.12. 13 The murine and human ligands for the flt3 receptor have recently been ~l o n e d . '~"~ flt3 ligand (FL) is a type I transmembrane protein that exists in both membrane-bound and soluble forms. FL mRNA was detected by Northern blot analysis in hematopoietic and nonhematopoietic tissues as well as in most hematopoietic cell lines surveyed.14"' This contrasts to flt3 receptor" (also known as flk-2'" or STK-1 'l) expression in the hematopoietic system, which has been found to be restricted primarily to adult mouse BM cells and hematopoietic precursor cells of the adult thymus, fetal thymus, and fetal liver." FL alone and in combination with other growth factors stimulates the proliferation of highly enriched human and murine hematopoietic progenitor/stem led to a deficiency of early B-cell precursors and multipoten-R cells,14-lh.2Z-21 T argeted disruption of the fit3 receptor gene treated controls. After 8 days of FL treatment, there was a maximal 123-and 108-fold increase in splenic CFU-GM and CFU-GEMM, respectively. The maximal number CFU-GM and CFU-GEMM were seen in PB on day IO, with 537-and 585-fold increases, respectively. Burst-forming units-erythroid (BFU-E) increased in the same time frame as those of CFU-GM and CFU-GEMM in BM, spleen, and PB, although the magnitude was not as great. Primitive day-l3 CFUspleen (CFU-S) and phenotypically defined stem cells were also mobilized into the PB of FL-treated mice with similar kinetics and magnitude to that of CFU-GM and CFU-GEMM. We conclude from these studies that FL, when administered as a single agent, is a potent mobilizer of hematopoietic progenitors into the PB. 0 1996 by The American Society of Hematology.
tial stem cells.25 Although many of the activities of FL on hematopoietic progenitor cells are similar to those of KL, there are clear differences. Most notably, FL has no known effect on the generation andor activation of mast cells.2h
To examine the effects of FL on hematopoietic cells in vivo, we injected mice for 15 days with recombinant Chinese hamster ovary (CHO)-cell-derived FL. In vitro colony assays were used to assess the effect of FL on the number of colony-forming units-granulocyte-macrophage (CFU-GM). burst-forming units-erythroid (BFU-E), and Cm-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM) progenitors in hematopoietic tissues over time. Primitive. multipotential day-I3 CFU-spleen (CFU-S) mobilized into the PB by FL treatment were also measured. Other hematopoietic parameters were assessed to fully evaluate FL activity, including hematocrit, leukocyte number, and phenotype. Our data show that the administration of FL to mice leads to the expansion and mobilization of hematopoietic progenitor/ stem cells, suggesting a potential clinical use of FL.
MATERIALS AND METHODS

Mice
Female C57BW6J mice (The Jackson Laboratory, Bar Harbor. ME), 8 to 12 weeks old (19 to 21 g of body weight), were used for all experiments. Mice were housed in a specific pathogen-free facility.
Expression of Soluble Human FL in C H 0 Cells
The extracellular portion of human FL was polymerase chain reaction (PCR)-cloned into the mammalian expression vector pCDE by PCR using primers: 5'-AATTCCCCGGGGCCGCCACCATGA-CAGTG-CTGGCGCCAGCCTG-3' and 5'-CGAACGCGGCCG-CTTACGGGGCTGTGGCCT-CCAGGGGCCGG, with a human FL" DNA as template. The resulting PCR product contained unique 5' Xma 1 and 3' Not I restriction sites and the coding sequence for the extracellular portion of FL extending from the methionine initiation codon through the PLEATAP sequence near the transmembrane region of the molecule." The fragment was ligated into Xrnu I-and Not I-digested pCDE expression vector and transformed into bacteria, and candidate clones containing inserts were sequenced to confirm there were no PCR-induced mutations. pCDE is a derivative of pCD302" containing the coding sequence for mouse dihydrofo- .29 pCDEHuFL, the final HuFL expression construct, was transfected into DHFR-CH0 cellsg0 using Ca" phosphate transfection. After a 48-hour expression period, the cells were split 1:lO into DHFR selection media lacking glycine, hypoxanthine, and thymidine (-GHT) and grown to confluence. Subsequently, the cells were plated in -GHT media containing 50 nmol/L methotrexate to coamplify the DHFR-and FL-transfected genes." When colonies formed, they were trypsinized and cloned using the dilution method in 96-well plates, and single-cell colonies were screened for soluble FL expression. C H 0 cell line 50-4 was used for the production of soluble FL.
Treatment of Mice
CHO-cell-derived human FL (0.025 ng endotoxidmg FL; Immunex Corp, Seattle, WA) was injected at 10 pg/mouse/d intraperitoneally (IP) or subcutaneously (SC), in low endotoxin phosphatebuffered saline (PBS) with low endotoxin mouse serum albumin (MSA) at 1 pg/mouse/d. Negative control mice received injections with MSA at 1 pglmouseld in PBS. Each experiment performed had 4-10 mice per group per time point. Spleens, BM and PB were pooled for CFU assays. Data presented are from a representative experiment that was performed a minimum of two times.
PB Cells
Twenty-four hours after the final injection, mice were anesthetized using Metofane (Pitman-Moore, Mudelin, IL). Blood was collected via cardiac puncture into heparinized tubes (Venoject; Fisher Scientific, Pittsburgh, PA). Hematocrits were obtained by centrifugation of blood in micropipets. Differential blood cell counts were obtained by examination of blood smears from each mouse stained with Wright-Giemsa stain (100 cells countedsmear). PB mononuclear cells (PBMNC) were isolated after centrifugation over a discontinuous gradient using Lympholyte-M (Cedarlane, Ontario, Canada). The mononuclear cells were collected and washed twice in PBS and then resuspended in supplemented (essential and nonessential amino acids, sodium pyruvate, vitamins, 2-mercaptoethanol, pennicilin, streptomycin, and glutamine) McCoys-Sa medium (Super McCoys) with 5% heat-inactivated fetal bovine serum (FBS). After individual PBMNC counts were made, cells from each group were pooled for analysis (colony assays, CFU-S assay, and phenotypic analysis).
Tissues
Femurs and spleens were aseptically removed and collected into cold PBS. Single-cell suspensions were prepared and clumps were removed using a 88-pm pore size filter (Nitex; Small Parts Inc, Miami, FL). Cells were washed once and then resuspended in Super
McCoys medium with 5% FBS. Cell counts were made on individual spleens and femurs before being pooled for analysis.
In Vitro Colony Assay
The frequency of CFU-GM, CFU-GEMM, and BFU-E in BM, spleen, and PB was analyzed using methylcellulose-based colony assays. Cells from BM, spleen, and PB were seeded in the colony assays at different concentrations (2-to 2.5-fold increments) based on tissue and prior treatment. Colony assays were performed using methylcellulose (HCC-3230; Stem Cell Technologies, Vancouver, British Columbia, Canada) supplemented with 100 ng/mL murine IL-3 (Immunex), 200 ng/mL murine KL (Immunex), 2 U/mL human erythropoietin (Stem Cell Technologies), and 0.2 mmol/L hemin3' (Eastman Kodak, Rochester, NY). Colony assays were plated in quadruplicate wells at 0.5 mL/well in 24-well plates (Costar, Cambridge, MA). Plates were incubated at 37°C in a humidified atmosphere containing 6.5% COz in air. After 9 days, colonies containing more than 50 cells were counted.
Day-l3 CFU-S Assay
Adult (3 to 5 months old) female C57BL/6J recipients were irradiated (950 R) using a 'j%s source (Mark 1 Irradiator; J.L. Shepherd and Associates, Glendale, CA) at a dose rate of 89 Wmin and were injected with donor PB cells 3 to 4 hours later. One million PBMNC cells from MSA-treated mice or a series of dilutions of cells (5 X l o 5 to 1 X lo4) from FL-(10 days at I O pg/mouse/d, SC) treated mice were injected intravenously (IV) into the lateral tail vein of lethally irradiated recipient mice (8 to 10 mice/group). Thirteen days after transplantation, recipient mice were killed and their spleens were excised and fixed in Teleyesniczki's solution. The macroscopic visible spleen colonies were counted.
Phenotypic Analysis
The spleens and BM of MSA-or FL-treated mice were isolated and pooled (N = 5). The cell-surface phenotypes of BM and spleen cells were analyzed by flow cytometry. All cells were incubated in PBS supplemented with 2% FBS, 0.02% Na Azide. One million cells per sample were incubated in a 100 pL volume for 30 minutes at 4°C. The following monoclonal antibodies (MoAbs) were used: NK1.l-phycoerythrin (PE), TERl19-PE, Gr-l-fluorescein isothiocyanate (FITC), Mac-I -PE, Thy I.Z-FITC, CDCPE, CD8a-PE, sIgM-FITC, and B220-FITC (Pharmingen, San Diego, CA). All samples were gated against labeled isotype-matched controls. To detect cells expressing a stem cell phenotype, PBMNC were isolated from PB, BM, and spleen by centrifugation over a discontinuous gradient (Lympholyte-M). Cells were incubated with a cocktail of lineagespecific MoAbs: B220-FITC. CD3-FITC, GR-I-FITC, Mac-I-FITC, and Sca-1 MoAb labeled with FluoroLink Cy5 reactive dye (Biological Detection Systems, Pittsburgh, PA) and biotinylated KL" for detection of the c-kit receptor. Biotinylated KL was detected with streptavidin-PE (Molecular Probes, Eugene, OR). All MoAbs were used at predetermined optimal concentrations. For general phenotypic analysis, 10.000 events were acquired using the FACScan flow cytometer (Becton Dickinson, San Jose, CA). For stem cell analysis, 100,000 events were acquired using the FACStar Plus flow cytometer (Becton Dickinson). Analysis of the acquired data was performed using Lysis I1 software (Becton Dickinson).
Statistical Analysis
Statistical analyses were performed using the unpaired two-tailed Student's t-test. To assess the effects of FL administration on circulating red blood cell (RBC) levels, the hematocrit of each mouse was determined. Daily administration of FL (10 pg/mouse/ d) by IP injection resulted in a modest, but significant decrease of hematocrit over time. The nadir was reached after 15 days of treatment (27% decrease v MSA control; Fig  IC) . Seven days after treatment, the hematocrit approached normal levels.
RESULTS
FL Efects on
To examine the effect of FL administration on the ratio of lymphocytes, granulocytes, and monocytes in the PB, differential counts were performed. The ratio of these cells had changed dramatically (Table 1) after IO days. There was a 3.4-, 9.8-, and 77.5-fold increase in the absolute number of lymphocytes, granulocytes, and monocytic cells, respectively ( Table l) . The monocytic cells detected included both immature and mature cells (data not shown). One week after cessation of FL treatment, blood differentials had almost returned to control levels (data not shown).
BM and spleen. The effect of FL administration on the cellularity of BM and spleen was also examined. There was no significant change in BM cellularity after 15 days of FL days treatment (6.7-fold over control: Fig IA) . One week after cessation of FL treatment, the leukocyte counts returned to the level measured in control animals. In a separate experiment designed to determine the opti- (Fig 2A) . In a separate experiment, the BM cells from mice treated with MSA or MSA plus FL (10 pg/ mouse/d, 10 days, SC) were isolated from 5 animals and pooled. The relative frequencies of T cells, B cells, natural killer (NK) cells, and developing erythrocytes, monocytes, and granulocytes were analyzed. Within the lymphoid compartment, the absolute numbers of CD4+ and CD8+ T cells were reduced ( Table 2 ). The number of mature B cells (B220+/sIgM+) was also reduced. However, the number of immature B cells (B220+/sIgM-) had increased and now comprised 30% of the BM cells. Within the myeloid population, the numbers of the Mac-l +/Gr-1 -monocytes and Macl-/Gr-l+ granulocytes increased more than fivefold. There was also an expansion of the myeloid Mac-l+/Gr-l+ cells. The number of immature erythroid cells identified with the TER119 antibody34 decreased 90% when compared with control mice. Interestingly, there was an increase in Thyl-/ CD8a+ cells that comprised 5% of the FL BM cells versus less than 1% in MSA (data not shown; see Discussion). A I n . 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 , Splenic cellularity increased 3.6-fold after 10 days of daily administration of FL (Fig 2B) . Seven days after cessation of FL treatment, cellularity had returned to control values. In a separate experiment, phenotypic analysis of splenocytes after 10 days of FL treatment (10 pg/mouse/d, SC) showed little change in the absolute number of CD4+ and CD8' T cells present (Table 2 ). There was a modest increase in NK1.1+ NK cells in the spleens of FL-treated mice. The most striking effect within the lymphoid compartment was the ninefold increase in the absolute number of immature (B220i/sIgM-) pre-B cells, although there was only a slight increase (< 1.5-fold) in the number of mature B cells. Similar to the effects seen in BM, there was an increase in cellularity in the myeloid compartment of the spleen; the number of Mac-l+/Gr-l+ cells had increased 17-fold, whereas the numbers of single-positive Mac-l+/Gr-1-and Mac-l-/Gr-l+ use only. 
FLT3L Daily
FL Effects on Hematopoietic Progenitor Numbers
Kinetics ofprogenitor cell expansion. Within the murine hematopoietic system, flt3 receptor expression is restricted primarily to multipotential progenitor cells and pro-B cells." To investigate the effects of FL on hematopoietic progenitor cells, we examined the BM, spleen, and PB of FL-treated mice for the frequency of clonal hematopoietic progenitors by in vitro assays. Numbers of GM colonies consisting of granulocyte and/or macrophage (GM) cells; mixed colonies consisting of granulocytes, erythrocytes, macrophage, and megakaryocytes (GEMM); and pure erthyroid colonies (BFU-E) were assessed.
The number of BM-derived CFU-GM increased fivefold in mice injected IP with 10 yglmouseld FL for 3 days compared with control animals (Fig 3A) . After the initial increase, CFU-GM declined during continued FL administration, reaching control values after 15 days of treatment. One week after the cessation of FL treatment, CFU-GM numbers were approximately half that of control mice. BFU-E numbers were variable in MSA-treated control mice (Fig 3B) . However, when BFU-E from FL-treated mice were compared with the MSA control, there was an increase in BFU-E only at day 3 of FL treatment. BM-derived CFU-GEMM had similar kinetics to those of CFU-GM. BM-derived CFU-GEMM peaked after 3 days of FL treatment and then subsequently returned to control levels after 8 days (Fig 3C) .
With daily FL administration there was an increase in splenic CFU-GM and CFU-GEMM that was maximal after 8 days of treatment (123-and 108-fold over control, respectively; Fig 3D and F) . Splenic BFU-E numbers showed a similar pattern of increase to CFU-GM and CFU-GEMM, although the peak number was not observed until day 10 of FL treatment and the magnitude of the increase was not as great (8.6-fold increase over control; Fig 3E) . After 10 days of FL treatment, all CFU began to decline until they had reached control levels 7 days after treatment.
The kinetics of CFU-GM, BFU-E, and CFU-GEMM expansion in the PB were slower than that observed in BM and spleens of FL-treated mice. The highest numbers of circulating CFU-GM, BFU-E, and CFU-GEMM were detected after 10 days of FL treatment (537-, 113-, and 585-fold increase over control, respectively; Fig 3G through I) . CFU-GM, BFU-E, and CFU-GEMM numbers returned to normal with the cessation of FL treatment.
In a separate experiment, we determined the dose of FL that was optimal to mobilize CFU into the PB. Mice were injected IP or SC with FL at four different doses for 10 days. PB was isolated and pooled (N = 4) for in vitro colony assays. Because the PB of mice were pooled, we could not use statisical analysis to determine whether there was a significant difference in mobilized CFU as a function of injection route. PB harvested from mice treated with FL at 0.6 or 2.5 yg/mouse/d showed little increase in CFU-GM, BFU-E, or CFU-GEMM (Fig 4A through C, respectively) . The maximal increase in CFU-GM in the PB was observed at a dose of 20 yg/mouse/d by both the IP and SC routes. FL injected at 20 yg/mouse/d mobilized more CFU-GM colonies (575-and 467-fold over control, by IP and SC, respectively), showing that 10 yg/mouse/d of FL was not saturating. However, FL at a dose of 10 yglmouse/d by IP and SC resulted in maximal CFU-GEMM mobilization into PB ( Fig  4C) . The optimal FL dose to mobilize BFU-E appeared to be depend on the route of injection, although we could not analyze this statisically (Fig 4B) .
FL Mobilizes Day-l3 CFU-S Progenitors
The CFU-S assay, originally described by Till and McCulloch,'6 is a functional assay that can measure primitive hematopoietic precursor cells that are capable of extensive proliferation and multiple lineage generation in the spleens of mice. We assayed FL-treated mice for the mobilization of day-l3 CFU-S into the PB. In this experiment, donor mice were treated with FL (10 yg/mouse/d, SC) for 10 days. PBMNC cells were harvested and pooled and then injected IV into lethally irradiated syngeneic recipient mice. Mice were killed 13 days after the injection of PB cells. In the same experiment, we also performed in vitro colony assays to compare with the day-13 CFU-S results. The absolute numbers of PB-derived CFU-GM, CFU-GEMM, and day-13 CFU-S per milliliter of blood from both MSA-and FLtreated mice are presented in Table 3 . The number of day-13 CFU-S progenitors increased 192-fold over control PB levels as a result of FL treatment.
Detection o j Stem Cells in FL-Treated Mice
The number of CD34' cells in the PB of humans undergoing stem cell mobilization procedures has been used as a measure of the frequency of hematopoietic progenitors/stem cells in the blood. We were interested in determining if we could detect cells with a stem cell phenotype in the pooled PB, BM, and spleens of mice after 10 days of FL treatment (10 pg/mouse/d). In the mouse, stem cells with the capacity of short-term and long-term reconstitution were defined as low-density, negative for lineage markers, Sca-l+, and ckit+. These cells were measured by flow ~ytometry.~' As expected, the frequency and total number of primitive LinSca-l 'c-kif+ cells was very low in all tissues from the MSAtreated mice (Table 4) , whereas the number of stem cells from the PB, BM, and spleens of FL-treated mice had increased 168-, 8.2-, and 1 13-fold, respectively.
DISCUSSION
We have examined the effects of administration of recombinant human FL on hematopoiesis in mice. As a single agent, FL elicits an increase (6.7-fold) in circulating WBC counts (Fig 1A) . Differential counts indicate an increase in the absolute number of circulating lymphocytes (3.4-fold), neutrophils (9.8-fold), and monocytes (77.5-fold) ( Table 1) . The kinetics of these changes in leukocyte cellularity are similar to those reported with KL, although the magnitude use only. of increase was less with KL, which mobilized primarily neutrophil^.^^ A modest decline in hematocrit was observed (Fig 1C) and may have been a result of RBCs sequestered in the spleens of FL-treated mice. Studies of FL in primates have shown no effect on circulating RBC or platelet levels. 39 We evaluated the effect of FL administration on hematopoietic precursor/stem cells using an in vitro colony assay. The number of BM-derived CFU-GM, BFU-E, and CFU-GEMM peaked at day 3 of 15 days of treatment (Fig 3A  through C) . As the CFU began to decrease in the BM after 3 days of FL treatment, splenic CFU began to increase and peaked after 8 to 10 days (Fig 3D through F) . There was a concurrent increase in PB CFU, which peaked by day 10 of treatment (>500-fold increase for CFU-GM and GEMM; Fig 3G through I) . The increased CFU in the spleens and PB of FL-treated mice reflected an increase in both the frequency of the CFU as well as the total cellularity of each respective tissue. These results suggest that CFU expansion occurs first in the BM and is followed by mobilization of progenitor/stem cells into the spleens and PB of mice. This contrasts with studies with growth factor (GF) treatments such as MIP-la or IL-8, which result in the immediate (ie, within minutes) mobilization of CFU from BM andor spleen to the PB.I2.l3
In addition, FL treatment increased the number of primitive day-l3 CFU-S in the PB ( Table 3) , showing that a full spectrum of CFU are mobilized by FL and that these stem cells are functionally competent to home to the spleen. Interestingly, the relative ratio of CFU-GM, BFU-E, CFU-GEMM, and CFU-S mobilized into the PB of FL-treated mice is similar to that seen in n o d BM (data not shown), suggesting that FL mobilizes a full range of hematopoietic progenitor cells. FL treatment also increased the absolute number of primative hematopoietic cells (Lin-Sca-l +c-use only. (Table 4 ). This population, in combination with a low Rhodamine 123 signal, has been shown to be highly enriched for long-term hematopoietic in vivo repopulating cells,j' and BRASEL ET AL To detect day-l3 CFU-S, recipient mice were lethally irradiated with 950 R and then injected with IO6 or 5 x lo4 pooled PBMNC from mice treated once a day for 10 days with 1 pg MSA or MSA plus 10 p g FL (SC), respectively. Recipient mice were killed 13 days later for scoring of macroscopic spleen colonies. An in vitro colony assay was also performed using PBMNC from the donor mice to compare with the CFU-S results.
* Absolute number per milliliter of blood.
we are currently in the process of evaluating FL-mobilized stem cells for this capacity.
We investigated the effects of FL treatment on the hematopoietic lineages in BM and spleen using flow cytometry. In the BM, FL treatment resulted in an increase in B-cell precursors (B220'/sIgM-) and myeloid cells (Mac-1 ' and Gr-l + ) and a 90% decrease in erythroid cells (Table 2 ). This effect on early B lymphopoiesis in the BM is consistent with the observation of reduced early B cells in Flt3 receptor knockout mice. 15 In the mouse, the spleen can act as an organ of hematopoiesis in response to G F treatment,"" and this was observed in FL-treated mice ( Fig 2B) . As seen in the BM, splenic B220'/slgM-B-cell precursors and myeloid cells were increased after I O days of FL treatment (Table  2) . These B-cell precursors were composed of both CD43+/ HSA+ pro-B cells and CD43 -/HSA' pre-B cells'" (data not shown). However, unlike the BM, there was a scvenfold Mice were treated with 1 pg MSA or MSA plus 10 p g FL for 10 days (SC). BM, spleen, and ?B cells were isolated and pooled to enumerate the frequency of low-density, lineage , Sca-l', c-kit' stem cells, as described in the Materials and Methods. The absolute number of stem cells per tissue was estimated from thefrequencyand mean cellularity ( 5 mice per group, except for the MSA PB group, which contained 10 mice). Our results show the capacity of FL to mobilize hematopoietic progenitor/stem cells into the PB of mice. FL has also been shown to mobilize these cells in nonhuman prim a t e~.~~.~~ These findings may have clinical significance because, with higher frequencies of progenitor cells per unit of blood, patients may require fewer aphereses for PB stem cell transplants. Although FL as a single agent has potent stem cell mobilizing effects, our recent investigations have shown a synergistic effect of FL plus G-CSF and FL plus GM-CSF in mobilizing stem cells into the PB."
